上海 复星医药 （集团）股份有限公司发布2025年度第二期科技创新债券募集说明书，本期债券注册金额40亿元，发行规模上限10亿元，期限2年，无担保，主体信用评级AAA。募集说明书详细披露了核心风险提示，包括应收账款回款、存货跌价、期间费用较大及行业政策调整等风险。同时，公司近期完成董事会换届，取消监事会，并修订《公司章程》以符合新法规要求。相关变动对日常管理及偿债能力不构成重大影响。
Source Link上海 复星医药 （集团）股份有限公司发布2025年度第二期科技创新债券募集说明书，本期债券注册金额40亿元，发行规模上限10亿元，期限2年，无担保，主体信用评级AAA。募集说明书详细披露了核心风险提示，包括应收账款回款、存货跌价、期间费用较大及行业政策调整等风险。同时，公司近期完成董事会换届，取消监事会，并修订《公司章程》以符合新法规要求。相关变动对日常管理及偿债能力不构成重大影响。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.